Research & Development
Pathology & AI
Microarrays and multiplexing
Hologic obtains FDA clearance for multiplex SARS-CoV-2/Flu A/Flu B/RSV assay
The Panther Fusion SARS-CoV-2/Flu A/B/RSV assay runs on the fully automated, high-throughput Panther Fusion system, which provides initial results in approximately three hours and can process more than 1,000 tests in 24 hours.
May 19, 2023
Aspira Women’s Health, Dana-Farber Cancer Institute ink agreement to develop ovarian cancer test
The test would use a Dana-Farber microRNA ovarian cancer signature with Aspira’s artificial intelligence/machine learning algorithms to identify ovarian cancer in patients with adnexal masses.
May 11, 2023
ChromaCode, MedGenome collaborate on multiplexing platform availability in India and the Middle East
The technology has a simplified workflow with the aim of enabling laboratories worldwide to perform high-quality, cost-effective testing internally, the firms said in a statement.
April 28, 2023
Akoya Biosciences launches panels for spatial biomarker discovery and validation
The PhenoCode Signature Panels are a hybrid of the company’s legacy Codex and Opal assays, and, when combined with the PhenoImager platforms, enable spatial phenotyping workflow, Akoya said.
November 8, 2022
QuantuMDx inks distribution agreement with Menarini
According to the agreement, Menarini will handle the distribution and marketing of the Q-POC platform, COVID assay, and QuantuMDx’s SARS-CoV-2/Flu A/B/RSV Respiratory Panel test in the U.K. and France.
November 2, 2022
Natera announces results for kidney test performance in predicting antibody mediated rejection
The Prospera test leverages Natera’s core single-nucleotide-based massively multiplexed PCR technology to identify allograft rejection noninvasively without the need for prior donor or recipient genotyping.
October 4, 2022
AMP 2021 meeting puts spotlight back on cancer
Seminars at AMP 2021 focused on technologies and techniques to help detect and profile tumors, with special emphasis on hard-to-detect cancer cells that remain in patients after treatment.
November 22, 2021
PathogenDx nabs CE-IVD Mark for DetectX-Rv test
DetectX-Rv will now be available for sale and distribution to qualified laboratories across the European Union. DetectX-Rv's microarray utilizes nasopharyngeal swabs and nasal aspirate or fluid to detect SARS-CoV-2 within three hours after RNA extraction.
July 21, 2021
Page 1 of 1